Daniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, Keun-Wook Lee, Matthew Ch Ng, Peter C Enzinger, Se Hoon Park, Philip J Gold, Jill Lacy, Howard S Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A Marrone, Ronan J Kelly, Rosalyn A Juergens, Jong Gwang Kim, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, Do-Youn Oh, Jennifer Yen, Justin I Odegaard, Errin Lagow, Daner Li, Jichao Sun, Patrick Kaminker, Paul A Moore, Minori Koshiji Rosales, Haeseong Park
PURPOSE: To assess the ability of circulating tumor DNA (ctDNA)-based testing to identify patients with HER2 (encoded by ERBB2)-positive gastric/gastroesophageal adenocarcinoma (GEA) who progressed on or after trastuzumab-containing treatments were treated with combination therapy of anti-HER2 and anti-PD-1 agents. METHODS: ctDNA analysis was performed retrospectively using plasma samples collected at study entry from 86 patients participating in the phase 1/2 CP-MGAH22-05 study (NCT02689284)...
April 25, 2023: Oncology (Williston Park, NY)